175 related articles for article (PubMed ID: 28633389)
21. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction.
Brownfoot FC; Hastie R; Hannan NJ; Cannon P; Tuohey L; Parry LJ; Senadheera S; Illanes SE; Kaitu'u-Lino TJ; Tong S
Am J Obstet Gynecol; 2016 Mar; 214(3):356.e1-356.e15. PubMed ID: 26721779
[TBL] [Abstract][Full Text] [Related]
22. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia.
Aggarwal PK; Chandel N; Jain V; Jha V
J Hum Hypertens; 2012 Apr; 26(4):236-41. PubMed ID: 21451568
[TBL] [Abstract][Full Text] [Related]
23. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia.
Staff AC; Braekke K; Johnsen GM; Karumanchi SA; Harsem NK
Am J Obstet Gynecol; 2007 Aug; 197(2):176.e1-6. PubMed ID: 17689641
[TBL] [Abstract][Full Text] [Related]
24. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
Levine RJ; Lam C; Qian C; Yu KF; Maynard SE; Sachs BP; Sibai BM; Epstein FH; Romero R; Thadhani R; Karumanchi SA;
N Engl J Med; 2006 Sep; 355(10):992-1005. PubMed ID: 16957146
[TBL] [Abstract][Full Text] [Related]
25. TGF-β and its coreceptors in cancerogenesis: an overview.
Todorović-Raković N; Milovanović J; Nikolić-Vukosavljević D
Biomark Med; 2011 Dec; 5(6):855-63. PubMed ID: 22103622
[TBL] [Abstract][Full Text] [Related]
26. Angiogenic profile and smoking in the Finnish Genetics of Pre-Eclampsia Consortium (FINNPEC) cohort.
Jääskeläinen T; Suomalainen-König S; Hämäläinen E; Pulkki K; Romppanen J; Heinonen S; Laivuori H;
Ann Med; 2017 Nov; 49(7):593-602. PubMed ID: 28537456
[TBL] [Abstract][Full Text] [Related]
27. Alterations of IL-6, IL-6R and gp130 in early and late onset severe preeclampsia.
Zhang Z; Gao Y; Zhang L; Jia L; Wang P; Zhang L; Li H
Hypertens Pregnancy; 2013 Aug; 32(3):270-80. PubMed ID: 23782174
[TBL] [Abstract][Full Text] [Related]
28. sFlt-1 and soluble endoglin concentrations in serum vs plasma in preterm preeclampsia: Are they interchangeable for biomarker studies?
Brownfoot F; Kaitu'u-Lino T; Beard S; Tong S; Hannan N
Pregnancy Hypertens; 2017 Oct; 10():18-21. PubMed ID: 29153675
[TBL] [Abstract][Full Text] [Related]
29. Soluble endoglin as a second-trimester marker for preeclampsia.
Robinson CJ; Johnson DD
Am J Obstet Gynecol; 2007 Aug; 197(2):174.e1-5. PubMed ID: 17689640
[TBL] [Abstract][Full Text] [Related]
30. Gestational angiogenic biomarker patterns in high risk preeclampsia groups.
Maynard SE; Crawford SL; Bathgate S; Yan J; Robidoux L; Moore M; Moore Simas TA
Am J Obstet Gynecol; 2013 Jul; 209(1):53.e1-9. PubMed ID: 23517919
[TBL] [Abstract][Full Text] [Related]
31. Soluble endoglin and transforming growth factor-beta1 in women who subsequently developed preeclampsia.
Lim JH; Kim SY; Park SY; Lee MH; Yang JH; Kim MY; Chung JH; Lee SW; Ryu HM
Prenat Diagn; 2009 May; 29(5):471-6. PubMed ID: 19253312
[TBL] [Abstract][Full Text] [Related]
32. Maternal serum transforming growth factor beta-2 in preeclampsia and eclampsia, a potential biomarker for the assessment of disease severity and fetal outcome.
Shaarawy M; El Meleigy M; Rasheed K
J Soc Gynecol Investig; 2001; 8(1):27-31. PubMed ID: 11223354
[TBL] [Abstract][Full Text] [Related]
33. Nicotine restores endothelial dysfunction caused by excess sFlt1 and sEng in an in vitro model of preeclamptic vascular endothelium: a possible therapeutic role of nicotinic acetylcholine receptor (nAChR) agonists for preeclampsia.
Mimura K; Tomimatsu T; Sharentuya N; Tskitishvili E; Kinugasa-Taniguchi Y; Kanagawa T; Kimura T
Am J Obstet Gynecol; 2010 May; 202(5):464.e1-6. PubMed ID: 20223446
[TBL] [Abstract][Full Text] [Related]
34. Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene.
Haiping Z; Takayama K; Uchino J; Harada A; Adachi Y; Kura S; Caicun Z; Tsuzuki T; Nakanishi Y
Cancer Gene Ther; 2006 Sep; 13(9):864-72. PubMed ID: 16710346
[TBL] [Abstract][Full Text] [Related]
35. Alteration of serum soluble endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset.
Hirashima C; Ohkuchi A; Matsubara S; Suzuki H; Takahashi K; Usui R; Suzuki M
Hypertens Res; 2008 Aug; 31(8):1541-8. PubMed ID: 18971528
[TBL] [Abstract][Full Text] [Related]
36. Release of endothelial cell associated VEGFR2 during TGF-β modulated angiogenesis in vitro.
Jarad M; Kuczynski EA; Morrison J; Viloria-Petit AM; Coomber BL
BMC Cell Biol; 2017 Jan; 18(1):10. PubMed ID: 28114883
[TBL] [Abstract][Full Text] [Related]
37. Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors.
Lim JH; Kim SY; Park SY; Yang JH; Kim MY; Ryu HM
Obstet Gynecol; 2008 Jun; 111(6):1403-9. PubMed ID: 18515525
[TBL] [Abstract][Full Text] [Related]
38. Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors.
Wong SH; Hamel L; Chevalier S; Philip A
Eur J Biochem; 2000 Sep; 267(17):5550-60. PubMed ID: 10951214
[TBL] [Abstract][Full Text] [Related]
39. Maternal plasma soluble endoglin at 11-13 weeks' gestation in pre-eclampsia.
Foidart JM; Munaut C; Chantraine F; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2010 Jun; 35(6):680-7. PubMed ID: 20205159
[TBL] [Abstract][Full Text] [Related]
40. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
